Skip to main content

GENETICA DE LA RESISTENCIA TUMORAL A LOS INHIBIDORES DEL PUNTO DE CONTROL IMMUNITARIO EN ORTHOXENOGRAFTS/PDOX DERIVADOS DE TRES TUMORES TRATADOS CON CISPLATINO: NSCLC, CANCER DE VEJIGA Y CÁNCER DE OVARIO

PI19/01320

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION IDIBELL
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.|||0000-0003-0229-6530
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Andrades, Álvaro
  • Trastulli, Deborah|||0000-0003-2407-3290
  • Pros, Eva|||0000-0002-2366-7866
  • Setien, Fernando|||0000-0002-4061-4635
  • Verdura, Sara|||0000-0001-8980-0423
  • Farré, Lourdes|||0000-0002-3168-1940
  • Martín-Tejera, Juan F.
  • Llabata, Paula|||0000-0001-7733-6475
  • Oaknin, Ana|||0000-0002-3592-7194
  • Saigí, Maria|||0000-0001-5815-5388
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Medina, Pedro P.
  • Vidal, August|||0000-0001-5727-2099
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gene amplification-associated overexpression of the selenoprotein trna enzyme trit1 confers sensitivity to arsenic trioxide in small-cell lung cancer

  • Coll-Sanmartin, Laia
  • Davalos, Veronica|||0000-0003-4077-5137
  • Piñeyro, David|||0000-0001-5633-3339
  • Rosselló-Tortella, Margalida|||0000-0003-4610-7981
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Setien, Fernando|||0000-0002-4061-4635
  • Villanueva, Alberto|||0000-0001-5164-0006
  • Granada, Isabel|||0000-0002-4275-0104
  • Ruiz-Xiviller, Neus
  • Kotter, Annika
  • Helm, Mark|||0000-0002-0154-0928
  • Yokota, Jun|||0000-0001-6010-6294
  • Kawabata-Iwakawa, Reika|||0000-0002-3504-1393
  • Kohno, Takashi|||0000-0002-5371-706X
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

  • Ortiz-Barahona, Vanessa
  • Soler, Marta|||0000-0002-6656-957X
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Janin, Maxime|||0000-0003-1013-4128
  • Setien, Fernando|||0000-0002-4061-4635
  • Fernández-Rebollo, Irene
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre, Carolina
  • Guil, Sonia|||0000-0002-2257-3331
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Zhang, Pei Hong
  • Yang, Li
  • Guarnacci, Marco
  • Schumann, Ulrike
  • Preiss, Thomas
  • Balaseviciute, Ugne
  • Montal, Robert
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Esteller, M.|||0000-0003-4490-6093
Background: RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. Methods: Combining data mining and conventional experimental procedures, NSUN7 methylation and expression status was assessed in liver cancer cell lines and primary tumors. Loss-of-function and transfection-mediated recovery experiments coupled with RNA bisulfite sequencing and proteomics determined the activity of NSUN7 in downstream targets and drug sensitivity. Results: In this study, the initial screening for genetic and epigenetic defects of 5-methylcytosine RNA methyltransferases in transformed cell lines, identified that the NOL1/NOP2/Sun domain family member 7 (NSUN7) undergoes promoter CpG island hypermethylation-associated with transcriptional silencing in a cancer-specific manner. NSUN7 epigenetic inactivation was common in liver malignant cells and we coupled bisulfite conversion of cellular RNA with next-generation sequencing (bsRNA-seq) to find the RNA targets of this poorly characterized putative RNA methyltransferase. Using knock-out and restoration-of-function models, we observed that the mRNA of the coiled-coil domain containing 9B (CCDC9B) gene required NSUN7-mediated methylation for transcript stability. Most importantly, proteomic analyses determined that CCDC9B loss impaired protein levels of its partner, the MYC-regulator Influenza Virus NS1A Binding Protein (IVNS1ABP), creating sensitivity to bromodomain inhibitors in liver cancer cells exhibiting NSUN7 epigenetic silencing. The DNA methylation-associated loss of NSUN7 was also observed in primary liver tumors where it was associated with poor overall survival. Interestingly, NSUN7 unmethylated status was enriched in the immune active subclass of liver tumors. Conclusion: The 5-methylcytosine RNA methyltransferase NSUN7 undergoes epigenetic inactivation in liver cancer that prevents correct mRNA methylation. Furthermore, NSUN7 DNA methylation-associated silencing is associated with clinical outcome and distinct therapeutic vulnerability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

  • Alcon, Clara
  • Martín, Fernando|||0000-0002-3496-9093
  • Prada, Estela|||0000-0003-4611-1120
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Soriano, Aroa|||0000-0001-9659-1471
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
  • Samitier, Josep|||0000-0002-1140-3679
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Montero, Joan|||0000-0002-9192-4836
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due to tumor adaptations. We used dynamic BH3 profiling to identify targeted agents effectiveness and anti-apoptotic adaptations upon targeted treatment in rhabdomyosarcoma. We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. We observed that the MEK1/2 inhibitor trametinib rapidly depleted the pro-apoptotic protein NOXA, thus increasing MCL-1 availability. Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. In conclusion, our findings indicate that the combination of a BH3 mimetic targeting MCL-1 with trametinib improves efficiency on rhabdomyosarcoma by blocking tumor adaptation to treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas, Marc|||0000-0002-2249-8554
  • Masiá, Nuria|||0000-0002-8352-2327
  • Suárez, Leticia|||0000-0002-3864-4616
  • Olivan, Mireia|||0000-0002-8464-0827
  • Soriano, Aroa|||0000-0001-9659-1471
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Burgos-Panadero, Rebeca
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Rodriguez-Sodupe, Pau
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Toledano, Ignasi|||0000-0003-0880-8904
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Navarro, Alexandra
  • Llobet Navas, David|||0000-0003-1443-7003
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Noguera, Rosa
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Krauss, Rolf
  • Gallego, Soledad|||0000-0002-4712-9624
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Segura, Miguel F.|||0000-0003-0916-3618